Grape King Bio Ltd (葡萄王), a supplier of probiotics and mushroom mycelium health foods, yesterday inked a three-year cooperation pact with China-based traditional Chinese medicine maker Yunnan Baiyao Group Co (雲南白藥) to codevelop new products and sell products in the Chinese and Southeast Asian markets.
The two companies are currently codeveloping two healthy drink products, one ointment and one pill, Grape King Bio said.
The two companies will jointly launch a health drink in Taiwan at the end of September, ahead of future launches in China and SouthEast Asia next year, Grape King Bio executive vice president Andrew Tseng (曾盛麟) said yesterday.
The company has the rights to sell products codeveloped by both in Taiwan, he said.
Yesterday’s deal also allows Grape King Bio to manufacture products for Yunnan Baiyao Group on a contract basis, while using raw materials provided by the Chinese firm in the new products.
The company will use its factories in Taiwan and Shanghai to make products for Yunnan Baiyao Group, he said.
Meanwhile, Grape King Bio can rely on Yunnan Baiyao Group’s retail channels in China and other oversea markets, including Southeast Asia, to sell its health food products that use raw materials from Yunnan Baiyao Group, Tseng said.
“As most of our revenue currently comes from the domestic market, the deal marks the entrance for Grape King Bio into the international market,” Tseng said.
According to Tseng, Grape King Bio tried to sell its “Come Best” tonic drink, products for improving digestion and mushroom mycelium health foods in China in the past without much success because it lacked a retail network.
The cooperation with Yunnan Baiyao Group may enable the company to enter the market more easily, he said.
Yunnan Baiyao Group is a Shenzhen-listed company with revenue of 15.8 billion yuan (US$2.54 billion) last year, and its market value, which was 82.8 billion yuan in October last year, was the highest among all Chinese medicine makers.
“It is the first time for Yunnan Baiyao Group to sign such a comprehensive cooperation pact with another company,” Tseng said.
From January through May, Grape King Bio posted revenue of NT$2.47 billion (US$82.52 million), up 8.34 percent from NT$2.28 billion a year ago, according to the company’s filing to the Taiwan Stock Exchange.
About 90 percent of its revenue was from Pro-Partner Inc (葡眾), a multi-level marketing company which sells Grape King Bio’s products in Taiwan, Tseng said.
Grape King Bio owns 60 percent of shares of Pro-Partner.
“It is a little bit risky for us to rely on Pro-Partner entirely,” Tseng said. “The cooperation with Yunnan Baiyao Group can become the second pilar of Grape King Bio.”
Shares of Grape King Bio rose 4.93 percent to NT$149 yesterday, outperforming the TAIEX, which was up 0.44 percent.
Semiconductor business between Taiwan and the US is a “win-win” model for both sides given the high level of complementarity, the government said yesterday responding to tariff threats from US President Donald Trump. Home to the world’s largest contract chipmaker, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), Taiwan is a key link in the global technology supply chain for companies such as Apple Inc and Nvidia Corp. Trump said on Monday he plans to impose tariffs on imported chips, pharmaceuticals and steel in an effort to get the producers to make them in the US. “Taiwan and the US semiconductor and other technology industries
SMALL AND EFFICIENT: The Chinese AI app’s initial success has spurred worries in the US that its tech giants’ massive AI spending needs re-evaluation, a market strategist said Chinese artificial intelligence (AI) start-up DeepSeek’s (深度求索) eponymous AI assistant rocketed to the top of Apple Inc’s iPhone download charts, stirring doubts in Silicon Valley about the strength of the US’ technological dominance. The app’s underlying AI model is widely seen as competitive with OpenAI and Meta Platforms Inc’s latest. Its claim that it cost much less to train and develop triggered share moves across Asia’s supply chain. Chinese tech firms linked to DeepSeek, such as Iflytek Co (科大訊飛), surged yesterday, while chipmaking tool makers like Advantest Corp slumped on the potential threat to demand for Nvidia Corp’s AI accelerators. US stock
The US Federal Reserve is expected to announce a pause in rate cuts on Wednesday, as policymakers look to continue tackling inflation under close and vocal scrutiny from US President Donald Trump. The Fed cut its key lending rate by a full percentage point in the final four months of last year and indicated it would move more cautiously going forward amid an uptick in inflation away from its long-term target of 2 percent. “I think they will do nothing, and I think they should do nothing,” Federal Reserve Bank of St Louis former president Jim Bullard said. “I think the
Cryptocurrencies gave a lukewarm reception to US President Donald Trump’s first policy moves on digital assets, notching small gains after he commissioned a report on regulation and a crypto reserve. Bitcoin has been broadly steady since Trump took office on Monday and was trading at about US$105,000 yesterday as some of the euphoria around a hoped-for revolution in cryptocurrency regulation ebbed. Smaller cryptocurrency ether has likewise had a fairly steady week, although was up 5 percent in the Asia day to US$3,420. Bitcoin had been one of the most spectacular “Trump trades” in financial markets, gaining 50 percent to break above US$100,000 and
RSS